Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension
Author(s) -
François Potus,
Grégoire Ruffenach,
Abdellaziz Dahou,
Christophe Thébault,
Sandra BreuilsBonnet,
Ève Tremblay,
Valérie Nadeau,
Renée Paradis,
Colin Graydon,
Ryan L. Wong,
Ian Johnson,
Roxane Paulin,
Annie C. Lajoie,
Jean Perron,
Éric Charbonneau,
Philippe Joubert,
Philippe Pîbarot,
Evangelos D. Michelakis,
Steeve Provencher,
Sébastien Bonnet
Publication year - 2015
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.115.016382
Subject(s) - downregulation and upregulation , medicine , angiogenesis , cd31 , heart failure , vascular endothelial growth factor , mapk/erk pathway , pulmonary hypertension , vascular endothelial growth factor a , neovascularization , endocrinology , cardiology , cancer research , kinase , biology , microbiology and biotechnology , vegf receptors , biochemistry , gene
Right ventricular (RV) failure is the most important factor of both morbidity and mortality in pulmonary arterial hypertension (PAH). However, the underlying mechanisms resulting in the failed RV in PAH remain unknown. There is growing evidence that angiogenesis and microRNAs are involved in PAH-associated RV failure. We hypothesized that microRNA-126 (miR-126) downregulation decreases microvessel density and promotes the transition from a compensated to a decompensated RV in PAH.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom